Skip to main content
Skip to main menu Skip to spotlight region Skip to secondary region Skip to UGA region Skip to Tertiary region Skip to Quaternary region Skip to unit footer


Seminar: Dr. Kim Lewis, "The Hunt For New Antibiotics:

An image of Kim Lewis
Dr. Kim Lewis
Northeastern University
C127 Davison Life Sciences and Zoom
Special Information:
Zoom link:

A major focus of my research is on antimicrobial tolerance, which limits the ability of antibiotics to eradicate an infection, and on antimicrobial drug discovery. We discovered that biofilm recalcitrance to treatment is due to the presence of dormant persister cells tolerant to killing by antibiotics. Our research shows that persisters are cells with low levels of ATP, which drops as a result of stochastic variation in expression of energy producing components. 

My group has been involved in antimicrobial drug discovery for over a decade. We developed methods to grow uncultured bacteria and to mine them for novel compounds. Of especial interest is teixobactin, a novel cell wall acting antibiotic that binds to different precursors of cell wall polymers and acts without the development of detectable resistance. In addition, lassomycin kills persister cells of M. tuberculosis by forcing the ClpC1 chaperone to deplete ATP. We also discovered that a known antimicrobial compound, ADEP, kills persisters by activating the proteolysis by the Clp protease in S. aureus.

More recently, we refocused our program on the identification of natural compounds acting against Gram negative pathogens, and discovered a new class of antibiotics, darobactins, inhibitors of BamA, an essential protein of the outer membrane, by using differential screening – testing a producer against two different bacterial species (in this case, E. colivs. S. aureus). We also developed an ultra-high-throughput differential screening based on incapsulating a single producer cell in a microdroplet containing two differently fluorescing reporter species. Further development and exploitation of this platform is the subject of the current proposal. Discovery of compounds acting against G- bacteria, and preliminary data on the discovery platform, were developed in the course of work on a recently completed PO1 grant AI118687 (PI/PD, K. Lewis; co-PIs, Karen Nelson, JCVI; Amy Spoering, NovoBiotic); 07/01/16-06/30/21, Resolving the bottleneck in antibiotic discovery.

Dr. Lewis's personal statement

Support us

We appreciate your financial support. Your gift is important to us and helps support critical opportunities for students and faculty alike, including lectures, travel support, and any number of educational events that augment the classroom experience. Click here to learn more about giving.

Every dollar given has a direct impact upon our students and faculty.